Harmony Biosciences Holdings (HRMY) Other Accumulated Expenses (2019 - 2026)

Harmony Biosciences Holdings (HRMY) has 8 years of Other Accumulated Expenses data on file, last reported at $41.9 million in Q1 2026.

• For the quarter ending Q1 2026, Other Accumulated Expenses rose 2372.33% year-over-year to $41.9 million; the trailing twelve-month figure through Mar 2026 stood at $41.9 million (up 2372.33% YoY), and the FY2025 full-year result was $65.8 million, up 27.2% from the prior year.
• Other Accumulated Expenses fell to $41.9 million in Q1 2026, from $65.8 million in the prior quarter.
• In the past five years, Other Accumulated Expenses ranged from a high of $65.8 million in Q4 2025 to a low of $773000.0 in Q4 2022.
• A 5-year average of $17.9 million and a median of $11.8 million in 2024 frame the typical range for Other Accumulated Expenses.
• Across the five-year window, Other Accumulated Expenses sank 93.25% in 2025 and surged 2372.33% in 2026, its largest moves.
• Tracing HRMY's Other Accumulated Expenses over 5 years: stood at $773000.0 in 2022, then soared by 910.35% to $7.8 million in 2023, then surged by 562.56% to $51.7 million in 2024, then climbed by 27.2% to $65.8 million in 2025, then sank by 36.33% to $41.9 million in 2026.
• Business Quant data shows HRMY's Other Accumulated Expenses at $41.9 million in Q1 2026, $65.8 million in Q4 2025, and $1.8 million in Q3 2025.